6-(2-chloro-pyridin-4-yl)-2-trifluoromethyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one | 933986-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 6-(2-chloro-pyridin-4-yl)-2-trifluoromethyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one
• 英文别名: 6-(2-Chloro-pyridin-4-yl)-2-trifluoromethyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one；6-(2-chloropyridin-4-yl)-2-(trifluoromethyl)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one
• CAS: 933986-18-6
• 化学式: C₁₂H₆ClF₃N₄O
• 分子量: 314.654
• InChiKey: AIGZSUJXHHJUJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-(2-chloro-pyridin-4-yl)-2-trifluoromethyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one 、 4,4,5,5-tetramethyl-2-styryl-[1,3,2]dioxaborolane 在 bis-triphenylphosphine-palladium(II) chloride 、 碳酸氢钠 作用下， 以 丙醇 为溶剂， 生成 6-[2-(2-Phenylethenyl)pyridin-4-yl]-2-(trifluoromethyl)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one
  参考文献：
  名称：

  Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity

  摘要：

  Pyrrolo-pyrimidones of the general structure 1 were synthesized and evaluated for their potential as MK2 inhibitors. Potent derivatives were discovered which inhibit MK2 in the nanomolar range and show potent inhibition of cytokine release from LPS-stimulated monocytes. These derivatives were shown to inhibit phosphorylation of hsp27, a downstream target of MK2 and are modestly selective in a panel of 28 kinases. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.039
• 作为产物：
  描述：

  2-amino-5-(2-chloro-pyridin-4-yl)-1H-pyrrole-3-carboxylic acid ethyl ester 、 三氟乙脒 生成 6-(2-chloro-pyridin-4-yl)-2-trifluoromethyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one
  参考文献：
  名称：

  BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2

  摘要：

  化合物的化学式(I)或其药学上可接受的盐或前药酯：其中，基团R1-R6，A和Y的定义如规范所述。

  公开号：

  US20090169558A1

文献信息

• [EN] BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2<br/>[FR] RÉACTIF DE LIBERATION POUR LES COMPOSÉS DE VITAMINE D
  申请人：NOVARTIS AG

  公开号：WO2007039285A1

  公开（公告）日：2007-04-12

  [EN] A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1-R6, A and Y are as defined in the specification, as inhibitors of (MK2 or MAPKAP kinase-2).
  [FR] La présente invention concerne une composition réactive pour la libération de composés de vitamine D liés à la protéine liant la vitamine D ainsi qu'un procédé de détection d'un composé de 25-hydroxyvitamine D. Dans ce procédé, le composé 25-hydroxyvitamine D est libéré à partir de la protéine liant la vitamine D en utilisant ce réactif et le mélange ainsi obtenu est analysé. L'invention concerne également l'utilisation du réactif visant à libérer des composés de vitamine D ainsi qu'un kit de détection de la 25-hydroxyvitamine D qui contient, outre les réactifs immunologiques habituels, le réactif de libération de composés de vitamine D.
• Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity
  作者：Achim Schlapbach、Roland Feifel、Stuart Hawtin、Richard Heng、Guido Koch、Henrik Moebitz、Laszlo Revesz、Clemens Scheufler、Juraj Velcicky、Rudolf Waelchli、Christine Huppertz

  DOI：10.1016/j.bmcl.2008.10.039

  日期：2008.12

  Pyrrolo-pyrimidones of the general structure 1 were synthesized and evaluated for their potential as MK2 inhibitors. Potent derivatives were discovered which inhibit MK2 in the nanomolar range and show potent inhibition of cytokine release from LPS-stimulated monocytes. These derivatives were shown to inhibit phosphorylation of hsp27, a downstream target of MK2 and are modestly selective in a panel of 28 kinases. (C) 2008 Elsevier Ltd. All rights reserved.
• BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2
  申请人：Heng Richard

  公开号：US20090169558A1

  公开（公告）日：2009-07-02

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1-R6, A and Y are as defined in the specification.

  化合物的化学式(I)或其药学上可接受的盐或前药酯：其中，基团R1-R6，A和Y的定义如规范所述。